PRCTHealthcare · Medical DevicesThe 15 Wall Street analysts covering PROCEPT BioRobotics Corp. hold a median 12-month price target of $21 — -5.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 3 Nov 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores PROCEPT BioRobotics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (71): The business earns solid, repeatable profits on what it owns.
Momentum (16): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on PRCT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −5.3% from it.
Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Oct 2026 | Barclays | Initiates | Overweight | $30 |
| 5 Aug 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 5 Aug 2026 | Evercore ISI Group | Maintains | Outperform | $30 → $23 |
| 5 Aug 2026 | Piper Sandler | Maintains | Overweight | $35 → $25 |
| 5 Aug 2026 | Piper Sandler | Maintains | Overweight | — |
| 5 Aug 2026 | TD Cowen | Maintains | Buy | — |
| 5 Aug 2026 | TD Cowen | Maintains | Buy | $34 → $28 |
| 5 Aug 2026 | William Blair | Downgrade | Market Perform | — |
| 5 Aug 2026 | William Blair | Downgrade | Market Perform | — |
| 28 July 2026 | UBS | Assumes | Neutral | $20 |
| 6 July 2026 | Truist Securities | Downgrade | Hold | $30 → $25 |
| 6 July 2026 | Truist Securities | Downgrade | Hold | — |
| 24 June 2026 | Evercore ISI Group | Initiates | Outperform | — |
| 11 June 2026 | Leerink Partners | Downgrade | Market Perform | — |
| 30 Apr 2026 | Piper Sandler | Reiterates | Overweight | — |
| 6 Mar 2026 | Baird | Initiates | Neutral | — |
| 2 Mar 2026 | Truist Securities | Maintains | Buy | — |
| 26 Feb 2026 | B of A Securities | Downgrade | Underperform | — |
| 26 Feb 2026 | Leerink Partners | Maintains | Outperform | — |
| 26 Feb 2026 | Oppenheimer | Downgrade | Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PRCT appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, PROCEPT BioRobotics Corp. returned −38.2% against +12.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 94% of US stocks
Cheaper than 36% of US stocks
Cheaper than 28% of US stocks
Cheaper than 84% of US stocks
Higher than 68% of US stocks
Higher than 59% of US stocks
Higher than 79% of US stocks
Higher than 19% of US stocks
Higher than 13% of US stocks
Higher than 27% of US stocks
Higher than 23% of US stocks
Higher than 83% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
PROCEPT BioRobotics Corp. has a market value of $1.2B and an enterprise value of $1.0B.
Revenue in the twelve months to 30 June 2026: $337.3M. The latest quarter grew 19.3% year on year.
Net income over the same four quarters: −$109.8M, a −32.5% net margin.
Diluted earnings per share, trailing twelve months: $−1.94.
Free cash flow in the twelve months to 30 June 2026: −$84.9M.
Trailing P/E: −12.6×; forward P/E: −18.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.22%, paying out 0% of earnings.
PROCEPT BioRobotics Corp. employs 888 people — $380K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own PROCEPT BioRobotics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
PROCEPT BioRobotics reported unaudited financial results for the quarter ended September 30, 2026. The headline says the company reaffirmed its 2026 financial guidance.
Why it matters — The quarterly results and reaffirmed guidance provide PRCT watchers with an update on the company’s financial performance and outlook.
Zacks Investment Research says PROCEPT BioRobotics has a combination of two key ingredients that may support an earnings beat in its upcoming report, and outlines key expectations.
Why it matters — PRCT watchers may find the article relevant for its preview of the company’s upcoming earnings report.
Seeking Alpha discusses PROCEPT BioRobotics’ Aquablation offering for symptom relief while preserving sexual and urinary functions, along with ongoing HYDROS placements. It notes that future equipment replacement and recurring consumables sales depend on continued procedure growth.
Why it matters — PRCT watchers may track whether procedure growth sustains the potential for equipment and consumables revenue described in the item.
PROCEPT BioRobotics said it will report its third-quarter 2026 financial results after market close on November 4, 2026. Management will host a conference call at 4:30 p.m. Eastern Time that day.
Why it matters — PRCT watchers can note the date and time when the company plans to release results and discuss them with management.
The DJS Law Group has reminded investors of a class action lawsuit against PROCEPT BioRobotics Corporation (NASDAQ: PRCT), alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. The law firm is contacting investors regarding their rights in the case.
Why it matters — A securities class action lawsuit against the company introduces legal and reputational risk that PRCT watchers would want to monitor.
The 15 Wall Street analysts covering PROCEPT BioRobotics Corp. have a median 12-month price target of $21, with estimates ranging from $16 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 15 analysts covering PROCEPT BioRobotics Corp., 5 rate it a Buy, 9 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks PROCEPT BioRobotics Corp. 51 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, PROCEPT BioRobotics Corp. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (71 of 100).
No one can know that. What the data says: the median 12-month target from 15 analysts implies -5.3% from the last close, and Ticker Nerd's factor model ranks PROCEPT BioRobotics Corp. 51 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering PROCEPT BioRobotics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRCT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $30 over the next 12 months.
PROCEPT BioRobotics Corp. returned -38.2% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company focused on urology.
The most recent item we track (GlobeNewsWire, 4 Nov 2026): "PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance". PROCEPT BioRobotics reported unaudited financial results for the quarter ended September 30, 2026. The headline says the company reaffirmed its 2026 financial guidance.
PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company focused on urology. The company develops, manufactures, and sells the AquaBeam Robotic System and the HYDROS Robotic System, both designed for image-guided, minimally invasive urologic procedures. Its core offering is Aquablation therapy, a robotic treatment approach used primarily for benign prostatic hyperplasia and related lower urinary tract symptoms. PROCEPT BioRobotics also supports its systems with consumables, service, and clinical workflow tools that help hospitals and urology practices deliver precise, patient-specific care. The company serves healthcare providers in the United States and selected international markets, positioning itself within the medical device and surgical robotics segments of the healthcare industry.
CEO Mr. Larry L. Wood · 888 employees · United States · https://www.procept-biorobotics.com
